Therapy

Exelixis

$22.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.82 (+3.85%) Today
-$0.14 (-0.63%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Exelixis and other stocks, options, and ETFs commission-free!

About EXEL

Exelixis, Inc. Common Stock, also called Exelixis, is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA. The listed name for EXEL is Exelixis, Inc. Common Stock.

CEO
Michael M. Morrissey
Employees
617
Headquarters
Alameda, California
Founded
1994
Market Cap
7.16B
Price-Earnings Ratio
46.27
Dividend Yield
—
Average Volume
3.31M
High Today
$22.29
Low Today
$21.13
Open Price
$21.24
Volume
3.73M
52 Week High
$27.80
52 Week Low
$13.67

Collections

EXEL Earnings

$0.00
$0.11
$0.23
$0.34
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Feb 10, After Hours

You May Also Like

VGAC+
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure